PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Positive EBIT growth while RVPH is negative. John Neff might see a substantial edge in operational management.
16.52%
Positive operating income growth while RVPH is negative. John Neff might view this as a competitive edge in operations.
16.61%
Net income growth under 50% of RVPH's 37.71%. Michael Burry would suspect the firm is falling well behind a key competitor.
17.14%
EPS growth under 50% of RVPH's 41.18%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
17.14%
Diluted EPS growth under 50% of RVPH's 41.18%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while RVPH stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
9.84%
Positive OCF growth while RVPH is negative. John Neff would see this as a clear operational advantage vs. the competitor.
13.18%
Positive FCF growth while RVPH is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2671.03%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.48%
Positive OCF/share growth while RVPH is negative. John Neff might see a comparative advantage in operational cash viability.
83.42%
Positive 3Y OCF/share CAGR while RVPH is negative. John Neff might see a big short-term edge in operational efficiency.
-2587.91%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
90.30%
Positive 5Y CAGR while RVPH is negative. John Neff might view this as a strong mid-term relative advantage.
86.48%
Positive short-term CAGR while RVPH is negative. John Neff would see a clear advantage in near-term profit trajectory.
1551.35%
10Y equity/share CAGR above 1.5x RVPH's 249.12%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-71.69%
Negative 5Y equity/share growth while RVPH is at 249.12%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-47.82%
Negative 3Y equity/share growth while RVPH is at 249.12%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Positive asset growth while RVPH is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
15.36%
Positive BV/share change while RVPH is negative. John Neff sees a clear edge over a competitor losing equity.
-14.09%
We’re deleveraging while RVPH stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.82%
Our R&D shrinks while RVPH invests at 32.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.34%
We cut SG&A while RVPH invests at 181.18%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.